This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Close Message for pharmaceutical industry jobs
FirstMedcommsJob is dedicated to putting job seekers looking for pharmaceutical industry jobs in touch with recruiters and employers.
Browse Jobs Search Jobs
Germany (160)
Switzerland (155)
France (125)
Belgium (58)
Italy (48)
Australia (13)
Spain (8)
Denmark (7)
Austria (4)
Russia (4)
China (1)
Japan (1)
Singapore (1)

To receive a FREE weekly email alert of all the latest pharmaceutical industry jobs added to our database enter your email address below.

Submit | Tell me more...

Sister sites:
Our sister site Our sister site
Partner sites:

At Burntsky Limited we work with a number of third parties in order to maximise the reach of the jobs posted with us including but not limited to:

JooblePartner Jooble
UK Jobs
Science Jobs

Industry News
23 May 2017 23:09Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE(TM) (Oxymetazoline HCL) Cream, 1%
DUBLIN, May 23, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced that Emmy® and Tony® award-winning actress and singer, Kristin Chenoweth will kick off the "Less Red, More You" campaign today a

23 May 2017 22:30Allergan Announces Pricing of Public Offering of Senior Notes to Refinance Existing Debt
DUBLIN, May 23, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it has priced an offering of €2.7 billion aggregate principal amount of senior unsecured notes (the "Notes") in 4 tranches in a registered public offering. The Notes

23 May 2017 22:00First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse
STAINES-UPON-THAMES, United Kingdom, May 23, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 pilot study assessing the ef

23 May 2017 21:14FDA approves first cancer treatment for any solid tumor with a specific genetic feature
SILVER SPRING, Md., May 23, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the a

23 May 2017 21:05Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer
SAN DIEGO and VANCOUVER, British Columbia, May 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients

23 May 2017 21:05Tocagen Reports First Quarter 2017 Financial and Business Results
SAN DIEGO, May 23, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2017 and business highlights. "Tocagen has made g

23 May 2017 21:01Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
COPENHAGEN, Denmark, May 23, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financia

23 May 2017 21:01Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
SAN DIEGO, May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its primar

23 May 2017 18:00Attorney General Brnovich, Rep. Carter Join CVS Health to Announce Availability of Naloxone at All CVS Pharmacy Locations in Arizona
PHOENIX, May 23, 2017 /PRNewswire/ -- Attorney General Mark Brnovich and State Representative Heather Carter joined CVS Health (NYSE: CVS) today in announcing an important step to increase access to the opioid overdose-reversal medicine naloxone by

23 May 2017 16:36Reciente publicación y solicitud de patente de apabetalone apoya su desarrollo continuado y éxito
CALGARY, Alberta, May 23, 2017 /PRNewswire/ -- Nature Reviews Nephrology y Pfizer Inc. tratan la inhibición bromodominio BET y apabetalone como candidatos a fármacos viables   Resverlogix Corp. ("Resverlogix" o la "Compañía") (TSX: RVX) hoy dest

23 May 2017 16:12StarGreen Capital Will Invest $100 million Over the Next Year to Support Entrepreneurs in California's Legal Medical and Recreational Cannabis Industries
BEVERLY HILLS, Calif., May 23, 2017 /PRNewswire/ -- StarGreen Capital announced today its plans to invest $100 million over the next year in California's legal medical and recreational cannabis industries. StarGreen will provide capital and busines

23 May 2017 15:34Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F6
SAN DIEGO, May 23, 2017 /PRNewswire/ -- Entest BioMedical Inc. (PINK: ENTB) and Its subsidiary, Zander Therapeutics Inc., discussed recently reported progress achieved by Regen BioPharma Inc. (licensor of NR2F6 technology to Zander Therapeutics fo

23 May 2017 14:30LowestMed Releases its Annual Lists of the Top 100 drugs filled by consumers in 2016
SALT LAKE CITY, May 23, 2017 /PRNewswire/ -- Today, LowestMed released its annual lists of the top 100 prescription drugs filled, in the U.S., by consumers using and not using health insurance. Topping the list of drugs filled using insurance is At

23 May 2017 14:15Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
DUBLIN, HERTFORDSHIRE, England and PITTSBURGH, May 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional efficacy and

23 May 2017 14:15Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
DUBLIN and HERTFORDSHIRE, United Kingdom and PITTSBURGH, May 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional eff

23 May 2017 14:07Teen Pregnancies Linked to Multiple Drug Prescriptions
CHEYENNE, Wyo., May 23, 2017 /PR Newswire/ -- Multiple drug prescriptions given to teenage girls correlate with more teen pregnancies, according to a study by the Wyoming Department of Family Services and HCMS Group, a health information company.

23 May 2017 14:04Loopback Analytics Helps UTMC Cut Readmissions and Increase Pharmacy Profitability with Data-Driven Meds to Beds Program
DALLAS, May 23, 2017 /PRNewswire/ -- Loopback Analytics' health care data integration and analytics platform has enabled the University of Tennessee Medical Center (UTMC) to reduce readmission rate among patients who were identified to be at high r

23 May 2017 14:00New Chairman of the Board will accelerate US growth for LindaCare
HARTFORD, Connecticut, May 23, 2017 /PRNewswire/ -- LindaCare is pleased to announce the appointment of Donald L. Deyo into the new role of Chairman of the Board, with immediate effect. Deyo is currently CEO of FemPulse, a company developing nove

23 May 2017 14:00Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives - EFIC-GRÜNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
BRUSSELS and AACHEN, Germany, May 23, 2017 /PRNewswire/ -- The European Pain Federation EFIC® in cooperation with the pharmaceutical company Grünenthal announced that six young research scientists in the field of pain will be awarded an EFIC-GRÜN

23 May 2017 14:00Strata Oncology, Inc. Announces Launch of StrataNGS(TM) Test
ANN ARBOR, Mich., May 23, 2017 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company, today announced the launch of its 2.0 test, StrataNGS, a custom-designed, 90-gene targeted assay focused on actionable genetic alterations in tumor
News last updated 23/09/2018 08:51:18
line graphic

Compatible with:

JobMate   Broadbean   Idibu

Site optimised for Internet Explorer 8+ / Firefox 3+
View a complete Jobs Listing

Credit cards image